Roads to the strategic targeting of ovarian cancer treatment

Irusta, Griselda

doi:10.1530/rep-19-0593

Cited by 6 publications

(5 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dysregulation of Wnt/β‐catenin can induce EMT in ovarian cancer, which is characterized by decreased expression of the epithelial marker, E‐cadherin, and increased levels of mesenchymal markers, such as vimentin ( 28 ). Suppression of the Wnt/β-catenin pathway should always be considered when developing alternative therapies for ovarian cancer ( 29 ). For example, XAV939 and ICG‐001, two Wnt/β-catenin inhibitors with different modes of action, reduced ovarian cancer cell proliferation by suppressing the expression of cyclin D1 and c-myc ( 30 ).…”

Section: Discussionmentioning

confidence: 99%

Exosome Component 4 Promotes Epithelial Ovarian Cancer Cell Proliferation, Migration, and Invasion via the Wnt Pathway

Xiong

Sun²,

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

BackgroundOf gynecologic malignancies, ovarian cancer is the leading cause of death, mainly due to the lack of sensitive tumor markers, which means it almost always presents at an advanced stage. Exosome Component 4 (EXOSC4) is involved in RNA degradation, but its role in epithelial ovarian cancer (EOC) is unclear.MethodsThe expression levels of EXOSC4 in EOC and normal ovarian tissue specimens were determined by immunohistochemical staining. The overall survival (OS) and progression-free survival (PFS) of patients with EOC were evaluated after patients were classified into high and low EXOSC4 expression groups, and the Cox regression model was established to identify independent predictors of patient prognosis. The effects of EXOSC4 on proliferation, colony formation, migration, and invasion were examined in the SKOV-3 and HO8910 cell lines by lentivirus-mediated shRNA knockdown. Flow cytometry was used to detect cell cycle changes. The mRNA levels of cyclin D1, CDK4, and c-myc were detected by RT-PCR. The protein expression levels of β-catenin, cyclin D1, CDK4, c-myc, vimentin, N-cadherin, and E-cadherin were assessed by western blot. Wnt/β-catenin activation was measured by TCF/LEF reporter assay.ResultsEXOSC4 was significantly elevated in EOC tissues and cell lines. High EXOSC4 expression was correlated with the International Federation of Gynecology and Obstetrics (FIGO) stage and pathological grade, and identified as an independent predictor of shorter OS and PFS. EXOSC4 knockdown suppressed proliferation, migration, and invasion in EOC cell lines. Cells were arrested at G0/G1 phase after EXOSC4 knockdown. The mRNA levels of cyclin D1, CDK4, and c-myc were decreased. β-catenin, cyclin D1, CDK4, c-myc, vimentin, and N-cadherin protein expression levels were reduced, while those of E-cadherin was increased. Wnt/β-catenin activity was suppressed after the EXOSC4 knockdown.ConclusionsEXOSC4 is involved in EOC. Knockdown of EXOSC4 can inhibit the proliferation, migration, and invasion ability of EOC by suppressing the Wnt pathway. EXOSC4 is expected to be a novel biomarker and molecular target in EOC.

show abstract

Section: Discussionmentioning

confidence: 99%

Exosome Component 4 Promotes Epithelial Ovarian Cancer Cell Proliferation, Migration, and Invasion via the Wnt Pathway

Xiong

Sun²,

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…The five-year survival of patients is very dependent on the early diagnosis and treatment of this cancer. 57 Although CA-125 (carbohydrate antigen 125 or cancer antigen 125) is used as a protein marker for the early diagnosis of ovarian cancer however in many noncancerous diseases (such as the liver, uterus, and gastrointestinal tract), the level of CA-125 increased in the blood. 58 Kobayashi et al 10 investigated the exosomal level of miR-1290 in the blood of ovarian cancer patients and the culture medium of ovarian cancer cell lines.…”

Section: Ovarian Cancermentioning

confidence: 99%

“…Ovarian cancer is the seventh most common cancer and the eighth leading cause of cancer death in women. The five‐year survival of patients is very dependent on the early diagnosis and treatment of this cancer 57 . Although CA‐125 (carbohydrate antigen 125 or cancer antigen 125) is used as a protein marker for the early diagnosis of ovarian cancer however in many noncancerous diseases (such as the liver, uterus, and gastrointestinal tract), the level of CA‐125 increased in the blood 58 .…”

Section: Role Of Mir‐1290 In Cancer Diagnosis and Prognosismentioning

confidence: 99%

The potential role of miR‐1290 in cancer progression, diagnosis, prognosis, and treatment: An oncomiR or onco‐suppressor microRNA?

Kalhori

Soleimani

Arefian

et al. 2021

J of Cellular Biochemistry

View full text Add to dashboard Cite

Cancer is one of the leading causes of death in humans because of the lack of early diagnosis, distant metastases, and the resistance to adjuvant therapies, including chemotherapy and radiotherapy. In addition to playing an essential role in tumor progression and development, microRNAs (miRNAs) can be used as a robust biomarker in the early detection of cancer. MiR‐1290 was discovered for the first time in human embryonic stem cells, and under typical physiological situations, plays an essential role in neuronal differentiation and neural stem cell proliferation. Its coding sequence is located at the 1p36.13 regions in the first intron of the aldehyde dehydrogenase 4 gene member A1. miR‐1290 is out of control in many cancers such as breast cancer, colorectal cancer, esophageal squamous cell carcinoma, gastric cancer, lung cancer, pancreatic cancer, and plays a vital role in their development. Therefore, it is suggested that miR‐1290 can be considered as a potential diagnostic and therapeutic target in many cancers. In addition to the importance of miR‐1290 in the noninvasive diagnosis of various cancers, this systematic review study discussed the role of miR‐1290 in altering the expression of different genes involved in cancer development and chemo‐radiation resistance. Moreover, it considered the regulatory effect of natural products on miR‐1290 expression and the interaction of lncRNAs by miR‐1290.

show abstract

“…Ovarian cancer (OV) is a common but fatal gynaecological malignancy. Although the mortality rate from OV has declined over the past 40 years as medical care has improved, it still remains the second leading cause of death from gynaecological cancers in women and the eighth leading cause of death in women ( Irusta, 2021 ). The current treatment for OV is mainly surgical resection and platinum-based chemotherapy, the combination of which usually brings good outcomes, with the addition of anti-angiogenic agents usually for poorly operated and stage IV patients ( Lheureux et al, 2019 ).…”

Section: Introductionmentioning

confidence: 99%

MCM10 is a Prognostic Biomarker and Correlated With Immune Checkpoints in Ovarian Cancer

Wang

et al. 2022

Front. Genet.

View full text Add to dashboard Cite

Background: Microchromosome maintenance protein 10 (MCM10) is required for DNA replication in all eukaryotes, and it plays a key role in the development of many types of malignancies. However, we currently still do not know the relationship between MCM10 and ovarian cancer (OV) prognosis and immune checkpoints.Methods: The Gene Expression Profiling Interactive Analysis and Tumor Immunology Estimation Resource (TIMER) databases were used to investigate MCM10 expression in Fan cancer. The Kaplan-Meier Plotter and PrognoScan were used to assess the relationship between MCM10 and OV prognosis. The LinkedOmics database was used to analyze the MCM10 co-expression network and explore GO term annotation and the KEGG pathway. The relationship between MCM10 expression and immune infiltration in OV was investigated using the Tumor Immunology Estimation Resource database. cBioPortal database was used to explore the relationship between MCM10 expression and 25 immune checkpoints. Finally, quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect MCM10 expression. The prognosis was also analyzed by distinguishing between high and low expression groups based on median expression values.Results: The results of the three data sets (220,651_s_at, 222,962_s_at and 223,570_at) in KM Plotter all indicated that the overall survivalof the high MCM10 expression group was lower than that of the low expression group OV, and the results of GSE9891 also reached the same conclusion. The expression level of MCM10 was negatively correlated with B cells and CD8+T cells, and positively correlated with CD4+T Cells and Macrophages. GO term annotation and KEGG pathway analysis showed that the co-expressed genes of MCM10 were mainly enriched in cell cycle and DNA replication. The alterations in MCM10 coexisted statistically with the immune checkpoints CTLA4, TNFSF4, TNFSF18, CD80, ICOSLG, LILRB1 and CD200. PCR results displayed that MCM10 was highly expressed in OV tissues, and the increased expression of MCM10 was significantly associated with poor overall survival.Conclusion: These results demonstrated that high expression of MCM10 was associated with poor prognosis in OV and correlated with immune checkpoints.

show abstract

Roads to the strategic targeting of ovarian cancer treatment

Cited by 6 publications

References 59 publications

Exosome Component 4 Promotes Epithelial Ovarian Cancer Cell Proliferation, Migration, and Invasion via the Wnt Pathway

Exosome Component 4 Promotes Epithelial Ovarian Cancer Cell Proliferation, Migration, and Invasion via the Wnt Pathway

The potential role of miR‐1290 in cancer progression, diagnosis, prognosis, and treatment: An oncomiR or onco‐suppressor microRNA?

MCM10 is a Prognostic Biomarker and Correlated With Immune Checkpoints in Ovarian Cancer

Contact Info

Product

Resources

About